These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11975192)

  • 1. In vitro screening of cytochrome P450 induction potential.
    Pelkonen O; Hukkanen J; Honkakoski P; Hakkola J; Viitala P; Raunio H
    Ernst Schering Res Found Workshop; 2002; (37):105-37. PubMed ID: 11975192
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121.
    Hudson SA; McLean KJ; Surade S; Yang YQ; Leys D; Ciulli A; Munro AW; Abell C
    Angew Chem Int Ed Engl; 2012 Sep; 51(37):9311-6. PubMed ID: 22890978
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography.
    Kool J; van Liempd SM; Ramautar R; Schenk T; Meerman JH; Irth H; Commandeur JN; Vermeulen NP
    J Biomol Screen; 2005 Aug; 10(5):427-36. PubMed ID: 16093552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.
    Crespi CL; Penman BW
    Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.
    Robin MA; Maratrat M; Le Roy M; Le Breton FP; Bonierbale E; Dansette P; Ballet F; Mansuy D; Pessayre D
    J Clin Invest; 1996 Sep; 98(6):1471-80. PubMed ID: 8823314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human drug metabolizing cytochromes P450.
    Wrighton SA; VandenBranden M; Ring BJ
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):461-73. PubMed ID: 9131485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
    Crivori P; Poggesi I
    Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
    Rodrigues RM; De Kock J; Doktorova TY; Rogiers V; Vanhaecke T
    Methods Mol Biol; 2015; 1250():279-85. PubMed ID: 26272150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validated assays for human cytochrome P450 activities.
    Walsky RL; Obach RS
    Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
    Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
    Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of three parallel cytochrome P450 enzyme affinity detection systems coupled on-line to gradient high-performance liquid chromatography.
    Kool J; van Liempd SM; van Rossum H; van Elswijk DA; Irth H; Commandeur JN; Vermeulen NP
    Drug Metab Dispos; 2007 Apr; 35(4):640-8. PubMed ID: 17251308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput fluorescence assay for cytochrome P450 mechanism-based inactivators.
    Kenaan C; Zhang H; Hollenberg PF
    Methods Mol Biol; 2013; 987():61-9. PubMed ID: 23475667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advance of studies on effect of resveratrol on activity of cytochrome P450].
    Lu Y; Huang ZJ; Yuan H
    Zhongguo Zhong Yao Za Zhi; 2013 Mar; 38(5):653-6. PubMed ID: 23724668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro models for in vivo drug profiles.
    Kling J
    Nat Biotechnol; 1996 Dec; 14(13):1655-6. PubMed ID: 9634846
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of promutagens in a human bronchial epithelial cell line stably expressing human cytochrome P450 1A2.
    Macé K; Gonzalez FJ; McConnell IR; Garner RC; Avanti O; Harris CC; Pfeifer AM
    Mol Carcinog; 1994 Oct; 11(2):65-73. PubMed ID: 7916994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The time to move cytochrome p450 induction into mainstream pharmacology is long overdue.
    Smith DA; Dickins M; Fahmi OA; Iwasaki K; Lee C; Obach RS; Padbury G; De Morais SM; Ripp SL; Stevens J; Voorman R; Youdim K
    Drug Metab Dispos; 2007 Apr; 35(4):697-8. PubMed ID: 17384203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.